Extended-Release Injectable Drugs: Technology, Therapeutics, Markets, & Forecasts
This new market study, “Extended-Release Injectable Drugs: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Engineered Injectables that Address Chronic Conditions
Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to produce APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.
What You Will Learn:
- What are the marketed Extended-Release injectable drug products, what Extended-Release formulation technologies are used, and who markets them?
- What are the major factors driving Extended-Release injectable drug demand?
- What Extended-Release injectable drug candidates are in late-stage clinical development and what is their potential impact?
- How important are drug developer-formulation technologist relationships in the Extended-Release market segment, and what are the key alliances in the industry?
- What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for Extended-Release injectable drug products?
- In what therapeutic market segments do Extended-Release injectables compete?
- What are the significant economic, technology, and regulatory factors affecting the market for Extended-Release injectables?
Table of Contents
- Injectable Drug Market Dynamics
- The Trend toward Self-Administration
- Injectable Drug Formulation Technology
- Innovation in Injectable Device Designs
- Therapeutic Demand Drivers
- Market Factors
- Patient Compliance and Ease of Use
- Healthcare Regulations
- Managed Care Initiatives
- Competitive Landscape
- Risk Factors
- Extended-release Formulation Technologies
- Biodegradable Polymers
- PEG
- PLA/PLGA
- Polyether ester
- Extended-release Formulation Platforms
- BEPO (MedinCell)
- ChroniJect (Oakwood Laboratories/PharmaSophia)
- CriticalMix (Critical Pharmaceuticals)
- Depofoam (Pacira)
- FluidCrystal (Camarus)
- LinkeRx (Alkermes)
- Medisorb (Alkermes)
- Medusa (Recipharm/Avadel)
- Nanocrystals (Alkermes)
- Optisomes (Talon/Spectrum)
- PolyActive (Octoplus)
- Q-Sphera (Midatech Pharma)
- SABER/SAIB (DURECT)
- SynBiosys (Innocore)
- TransCon (Ascendis)
- Physical Process Control Methods
- Supercritical Fluid
- SCF for Nanoparticle Formulations
- Formulplex (Supercritical Solutions)
- Ferro
- SCF extraction of emulsions (SFEE)
- Extended-release Injectables - Development Factors
- Formulation Factors
- Stability
- Administration Factors
- Extended Release Injectables - Product Analysis
- Aripiprazole
- Aripiprazole lauroxil
- Bupivacaine
- Buprenorphine
- Cytarabine
- Cytarabine & Daunorubicin
- Doxorubicin
- Estradiol
- Exenatide
- Fluphenazine decanoate
- Goserelin acetate
- Granisetron
- Interferon
- Irinotecan
- Lanreotide acetate
- Leuprolide
- Leuprolide Depot
- Medroxyprogesterone
- Naltrexone
- Octreotide acetate
- Olanzapine Pamoate
- Paliperidone palmitate
- Pasireotide
- Pegvaliase-pqpz
- Risperidone
- Testosterone
- Triptorelin
- Triamcinolone acetonide
- Vincristine sulfate
- Glycemic Control
- AB101 (Rezolute)
- Hormone Deficiency
- human Growth Hormone/Ascendis
- Addiction
- CAM2038 (Camurus)
- Pain Management
- Posidur/Durect
- Cardiology
- Treprostinil/Ascendis Pharma
- Neurology
- Relday/Risperidone (DURECT/Zogenix)
- Oncology
- CAM2032 (Camurus)
- Extended-Release Injectables - Selected Sector Analysis
- Addiction
- Glycemic Control
- Infectious Disease
- Hepatitis
- Neurology
- Schizophrenia
- Bipolar Disorder
- Oncology
- Pain Management
- Reproductive Health
- Fertility
- Endometriosis
- Vasomotor Symptoms associated with Menopause
- Company Profiles
- Alkermes
- Amylin
- AntriaBio
- Ascendis Pharma
- AstraZeneca
- Aurobundo
- Avadel
- Biomarin
- Camurus
- Critical Pharmaceuticals
- DURECT
- Eli Lilly
- Enzon
- Ipsen
- Janssen
- NanOlogy
- Novartis
- OctoPlus
- Oakwood Laboratories/PharmaSophia
- Pacira
- PhaseBio Pharmaceuticals
- Recipharm AB
- Roche
- Sanofi
- Taiwan Liposome Company (TLC)
- Xbrane Bipharma
